Treatment of malignant pleural effusion in non-small cell lung cancer with VEGF-directed therapy

Background Vascular endothelial growth factor (VEGF) is a critical regulator of malignant pleural effusion (MPE) in non-small-cell lung cancer (NSCLC). Bevacizumab (BEV) and apatinib (APA) are novel VEGF blockers that inhibit lung cancer cell proliferation and the development of pleural effusion.Met...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Zhangqiang Xiang, Xiangyu Deng, Wenfeng He, Qian Yang, Laichao Ni, Marzieh Dehghan Shasaltaneh, Mazaher Maghsoudloo, Gang Yang, Jingbo Wu, Saber Imani, Qinglian Wen
Formato: Artigo
Idioma:Inglês
Publicado em: Taylor & Francis Group 2022-12-01
Colecção:Annals of Medicine
Assuntos:
Malignant pleural effusion
non-small-cell lung cancer
vascular endothelial growth factor
bevacizumab
apatinib
cisplatin
Acesso em linha:https://www.tandfonline.com/doi/10.1080/07853890.2022.2071977
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados